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ABSTRACT PROTOCOL
Introduction: In recent decades, diabetes has contributed significantly to the burden of disease 
in developed and developing countries, due to the considerable prevalence and involvement 
of various age groups in the communities. Today, a variety of ways to manage and control the 
disease are used, one of which is the use of personal electronic health records. Recently there 
has been a remarkable upsurge in activity surrounding the adoption of personal electronic health 
records systems for patients and consumers. personal electronic health records systems are 
more than just static repositories for patient data; they combine data, knowledge, and software 
tools, which help patients to become active participants in their own care. The present study was 
conducted with the goal of Health Technology Assessment the impact of personal electronic 
health records in Patients with Diabetes. Methods and Analysis: Writing is based on PRISMA 
standards. This was a Health Technology Assessment study. It aimed to evaluate the technology 
of personal electronic health record. The scoping review was conducted to evaluate 8 dimensions 
(Health Problem and Current Use of the Technology, Description and technical characteristics 
of technology, Safety, Costs and economic evaluation, Ethical analysis, Organizational aspects, 
Patients and Social aspects, Legal aspects) of Personal electronic health record. This study was 
based on answering questions which were developed based on Health Diagnostics Technology 
Assessment Documents Framework and Health Technology Assessment (HTA) Core Model 3.0. 
A systematic review was conducted to evaluate the Clinical Effectiveness dimension of personal 
electronic health record in controlling diabetes. In order to gather evidences, Ovid databases, 
Cochrane Library, PubMed, CRD, Trip database and EMBASE, and Randomized Controlled 
Trial Registries, such as the Clinical Trial and Trial Registry, were searched using specific 
keywords and strategies. Articles are evaluated on the basis of the quality criteria of JADAD. 
The data is analyzed by the STATA software. Dissemination: The results of the study will be 
published in a peer-reviewed journal and presented at relevant conferences. Policy makers and 
healthcare decision-makers can use these results.
INTRODUCTION
Diabetes is a metabolic disorder that leads to absent the 
ability of the body to produce insulin or make the body to 
resistance against insulin; so, the produced insulin may not 
do its normal function, and finally, the blood glucose will in-
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crease. In long-term, the excessive amounts of blood glucose 
level may damage various parts of the body such as cardio-
vascular system, eyes, kidneys, genital system, and nervous 
system (1-3). In recent years, the incidence of diabetes has 
increased in worldwide (4). According to latest statistics, the 
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global prevalence of diabetes reached to 382 million peo-
ple in 2013. It is predicted that in 2035, it will reach about 
592 million people (5). In Iran, the number of individuals who 
were infected with this disease was 9.9% in 2013; according 
to predictions, it will reach to 10.1% in 2035 (6). Nowadays, 
diabetes is epidemic in the world; the world’s prevalence of 
diabetes increases by about 6% annually. Considering the in-
creased prevalence of diabetes in the world, the treatment, 
control, and acute complications of diabetes require consid-
erable expenditure by both patients and community health 
system. In a report which was published in 2001 by World 
Health Organization (WHO), in which the global burden of 
diseases was calculated, diabetes ranked 20th in years lived 
with disability; in other words, 1.4% Years lost due to disabil-
ity (YLD) was associated with this disease (7).
The economic and physical consequences of diabetes are 
significant; it increases mortality and causes a lot of econom-
ic burdens (8). However, the negative consequences of dia-
betes may be prevented (9). The effective care and disease 
management are the only available solutions. The manage-
ment of diabetes is complex and requires basic healthcare, 
coordinated care, nutritionist and endocrine experts’ coop-
eration, etc. The patient education including proper lifestyle, 
healthy nutrition, having physical activity, and appropriate 
use of medications therapy is necessary to facilitate con-
trolling blood glucose levels (10). However, the increased 
number of people with diabetes, low numbers of primary 
care providers, and increasing healthcare costs have made it 
harder to take care of diabetic patients. In 2001, the National 
Academy of Medicine presented a solution to this problem 
which was known as improving communication between pa-
tients with chronic disease and self-care (11).
The improved knowledge and performance of patients 
with diabetes mean improved metabolic situation control 
and performing proper self-care behaviors (12). Therefore, 
the patients with diabetes will take care of him/herself well 
if he/she will be aware of his/her illness and treatment, tests, 
drugs, medical recommendations, follow-up visits, and 
blood glucose monitoring blood glucose levels. Indeed, the 
patients need conditions through which they may partici-
pate more in making decisions about their health status.To 
achieve this, the electronic personal health record (ePHR) 
is one of the appropriate tools which also empowers pa-
tients (13, 14). The concept of ePHR has existed from the 
past and is not new. In the past, the patients hold their health 
information in paper form. Archer et al. (2011) reported 
that among 47% of patients who keep their health records, 
87% stated that they keep them in paper form.Nowadays, 
the ePHR maintains the health and medical information 
of people in electronic form and they are available at any-
time (15). The ePHR is an electronic software in which peo-
ple access and manage their medical information. Hence, 
people may access to this confidential information in a se-
cure medium (16).
This study aims to evaluate the technology of ePHR 
in patients with diabetes compared with those who only 
received routine services and have not used ePHR. It can 
helped policy-makers in entry, design, and how to use it.
In dictionary of International Bureau of Health Tech-
nology Assessment (HTAi), this field is defined as HTA is 
a systematic evaluation of clinical effectiveness, cost-effec-
tiveness, or social and ethical effects of health technology 
on patient’s life and healthcare system. This process spec-
ifies that whether the desired health technology should be 
used (17). If so, how should it be used and which patients 
will benefit most from it? The evaluations are different, but 
it mostly focuses on cost and impact of technology on pop-
ulation or society.
According to this definition, the HTA studies address 
various dimensions of health technologies impacts; these 
dimensions may be divided into nine general domains in-
cluding (health problem and current use of the technolo-
gy, description and technical characteristics of technology, 
safety, clinical effectiveness, costs and economic evalua-
tion, ethical analysis, organizational aspects, patients and 
social aspects, and legal aspects) The examination of these 
technology dimensions effects and their related results may 
influence policy-maker and decision-making.The HTA Core 
Model is a methodological framework for collaborative 
production and sharing of HTA information. The HTA Core 
Model is a registered trademark. According to HTA Core 
Model 3.0, the technology dimensions study in HTA in-
cludes some elements; questions should be answered in 
each element (18).
METHODOLOGY
This was a HTA study. It aimed to evaluate the technology of 
ePHR. The scoping review was conducted to evaluate 8 di-
mensions (health problem and current use of the technolo-
gy, description and technical characteristics of technology, 
safety, clinical effectiveness, costs and economic analysis, 
ethical issue, organizational aspects, patients and social as-
pects, and legal aspects) of ePHR. This study was based on 
answering questions which were developed based on Health 
Diagnostics Technology Assessment Documents Framework 
and HTA Core Model 3.0 (18). A systematic review was con-
ducted to evaluate the clinical effectiveness dimension of 
ePHRin controlling diabetes.
Questions
Databases including Cochrane library, PubMed, Center for 
Review and Dissemination(CRD), Trip database, and EM-
BASE, randomized controlled trial (RCT) studies register 
databases (such as Clinical Trial and Trial Registry) were 
searched bykeywords as follow: personal health record, per-
sonal medical records, ePHR, diabetes mellitus, and records. 
The search was performed without any time and language 
limitation.The final articles were collected for systematic 
review based on the process of selecting specific resourc-
es; their quality was evaluated based on Critical Appraisal 
Skills Program (CASP) critical evaluation checklist which is 
designed for RCT studies. The structured questioning com-
ponents (PICOD) at population, intervention, comparison, 
outcome, and design levels are as follows Table 1 and 2 both 
here .
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Examined 
dimension
Questions Answers
1-Health problems 
and current 
technology use
What disease or major health problem is the target of intervention?
Define diabetes disease and categorize it?
What are the symptoms of diabetes?
What are the risk factors for diabetes?
What are the outcomes and consequences of disease?
How many people are in the group of patients with diabetes?
What is the burden of diabetes?
What is the rate of applying ePHR technology?
How the application of ePHR technology varies in different countries, regions, and programs?
How developed is the ePHR technology (study, emerging, stabilized, declining phases)?
Does ePHRtechnology fall into the basic services package of different countries? What is 
the coverage of technology in other countries?
Who produces PHR technology?
Scoping review
2- Technology 
features
What is ePHR? How is the scientific foundation and mechanism of its effect?
Why is ePHRused?
For whom the ePHR technology is applicable?
Is public information about technology necessary? What information is needed to inform people?
What are capital factors required to use ePHR technology?
What kind of specific platform is required to use ePHR technology?
What type of equipment is required to use ePHR technology?
What types of data are required to monitor the application of ePHR technology?
What type of training or information on PHR technology is required to be provided to 
patients, their families, and the general public?
What are the proven and potential applications of ePHR technology?
Scoping review
3-safety What are the potential risks and possible damages of PHR technology?
What is the range of risks which are associated with ePHR technology; incidence, severity, 
duration?
How is the prevalence of technology-related damages?
When damage occurs (immediately or delayed)?
Which of the damages which are associated with ePHR technology are more important 
considering their prevalence and severity?
Does the prevalence of ePHR-related damage changes over time?
How ePHR technology is safe compared to alternative technologies?
What are the ways to reduce user-related safety risks?
Is there any evidence of environmental damages?
What kind of environmental protection is needed?
Scoping review
4- Effectiveness What is the effect of ePHR technology on overall mortality?
What is the effect of ePHR technology on the mortality rate of target disease?
What is the effect of ePHR technology on mortality which is caused by other reasons?
What is the effect of ePHR technology on severity and frequency of disease symptoms and 
findings?
What is the effect of ePHR technology on the progression of disease?
What is the effect of ePHR technology on recurrence of disease symptoms?
What is the impact of ePHR technology on health-related life quality?
What is the impact of ePHR technology on quality of life which is associated with target 
disease?
What is the effect of ePHR technology on patient’s return to work and previous life 
situation?
What is the impact of ePHR technology on patient’s daily activities?
Is ePHR technology valuable to the patient?
Systematic 
review
5- Costs and 
economic 
assessment
What types of resources are used to provide evaluated technology and comparing 
it (identification of used resources)?
How many resources are used in providing evaluated technology or competing 
technologies (costs which are specifically related to technology)?
What is the unit price of consumed resources at the time of providing evaluated technology 
and its comparators?
What is the effect of PHR technology on indirect costs?
What are the incremental effects of technology relative to comparators?
What is the incremental cost-effectiveness ratio?
Scoping review
(Contd...)
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6-Ethical Is ePHR technology a new and innovative technology which adds to standard care or 
replaces a standard?
Does ePHR technology challenge the religious, cultural, or spiritual principles and beliefs 
of some groups or change the current social principles of society?
What are the unanticipated and unwanted results and implications of ePHR technology?
Does the use of ePHR technology affect the patient’s ability?
Does PHR technology have any risks or challenges that the patient needs to know it?
Does the institutionalization and use of ePHR technology affect human status?
Does institutionalization and use of ePHR technology affect human dignity?
What are the benefits and dangers for the patients, and how will there be a balance 
between the benefits and risks when the technology is institutionalized and when it is not 
institutionalized? Who creates a balance between risks and benefits? And how?
Can ePHR technology harm other stakeholders?
What are the effects of institutionalizing and not institutionalizing of technology on justice 
in health care? Are the principles of equality, justice, and integrity respected?
Scoping review
7-Organizational What kind of workflow and disease flow will be required?
What kind of partnership of patients and relatives is needed to be developed in the process 
of treatment and care?
What type of staff training and other human resources is needed?
What will be the results of the centralized and decentralized expansion of implementing 
new technology?
What investment (material and immaterial) should be undertaken to set up and expand 
technology?
What effect will the technology implementation have on government spending and 
budgets?
What are the challenges and management opportunities which are associated with 
technology?
Who decides about whether the patient uses ePHR technology?
How will the new ePHR technology be accepted?
Scoping review
8-Social What social domains are affected by ePHR technology?
In addition to the patient, what is the effect of technology on other important people?
What kind of support and resources are needed when PHR technology is used?
How will technology affect the position, role, and functions and important life issues of the 
patient in society?
How the use of ePHR technology changes the physical and psychological functioning of 
patients in main living areas?
How do patients and other important people react to ePHR technology?
How is the understanding and knowledge of patients and other important people about 
ePHR technology?
How are the information on using ePHR technology analyzed and exchanged?
Scoping review
9-Legal Whether the use of technology by patient needs an informed consent from the patient?
Whether in the case of using alternative technologies of evaluated technology, the patients 
should be informed?
Considering patient’s conditions, whether they have enough time to decide on technology?
Is it possible to obtain the informed consent of the patient before using technology?
Does the use of technology require access to personal and private information of patient?
Do all people need (or will have) same access to evaluated technology?
Does the technology require a specific registration mechanism?
Does the technology need a specific assessment and monitoring mechanism?
Are there enough rules for technology use?
Are certain rules and regulations required for using technology? What areas are considered 
in using these rules?
Coping review
Examined 
dimension
Questions Answers
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Table 1. Structured questioning components (PICOD)
Population Patients with diabetes
Intervention ePHR
Comparison received regular care
Outcome Health problems and current use of the 
technology, description and technical 
characteristics of technology, safety, clinical 
effectiveness, costs and economic evaluation, 
ethical issue, organisational aspects, patients 
and social aspects, legal aspects
Design HTA, systematic review, RCT, non 
Clinical -trial studies, economic evaluation, 
guidelines
Table 2. Applied search strategy in electronic databases
CRD York
SearchesResult
0(Personal Health Record OR Personal Health 
Records OR Personal Medical Records ) 
AND (Diabetes Mellitus, Type 1 OR Diabetes 
Mellitus, Type 2 OR Glucose Intolerance OR 
Diabetic Ketoacidosis OR Diabetes Insipidus): TI 
IN DARE, NHSEED, HTA
Search Name Cochran: library
ID Search hits Items 
found
#1 Personal health record: ti, ab, kw (Word 
variations have been searched)
374
#2 Personal health records 1682
#3 Personal medical records/ 1531
#4 Computerized patient records/ 612
#5 ePHR s/ 1426
#6 patient-held record 51
#7 personally controlled health record 103
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7 2404
#9 Diabetes Mellitus, Type 1 18472
#10 Diabetes Mellitus, Type 2 21837
#11 Glucose Intolerance 1356
#12 Diabetic Ketoacidosis 375
#13 Diabetes Insipidus 139
#14 #10 or #11 or #12 or #13 or #14 24447
#15 #9 and #15 366
#16 #9 and #15 Publication Year from 2000 to 
2016, in Trials
27
Selection of studies
The phase of searching and reviewing quality of articles 
will be done by two individuals independently. In the case 
of disagreement, the judgment was made by the third per-
son. After completing the search, all found articles were 
entered into EndNote software, and the duplicates items 
will be deleted.Then, the titles and abstracts of articles 
will be reviewed by two people based on inclusion and 
exclusion criteria. In the case of unclear title and abstract, 
the full text was extracted. Also, articles’ references will 
be reviewed and the related studies will be searched.The 
inclusion and exclusion criteria in the first (based on title 
and abstract) and second (based on full text) stages are as 
follows:
Inclusion and exclusion criteria of study
• Population:
Items 
found
QuerySearch
844 ((((“”Personal Health Record “”[Title/
Abstract]) OR “”Personal Health 
Records “”[Title/Abstract]) OR 
“”Personal Medical Records””) OR 
“”Personal Electronic Health Records 
“”) OR “”Personal Electronic Health 
Records “”[Title/Abstract]”,
1#
177851(((((“”Diabetes Mellitus””[Title/
Abstract]) OR “”Diabetes Mellitus, 
Type 1 “”[Title/Abstract]) OR “”Diabetes 
Mellitus, Type 2 “”[Title/Abstract]) 
OR “”Glucose Intolerance “”[Title/
Abstract]) OR “”Diabetic Ketoacidosis 
“”[Title/Abstract]) OR “”Diabetes 
Insipidus””[Title/Abstract]”,
2#
21 ((((((“”Personal Health Record 
“”[Title/Abstract]) OR “”Personal 
Health Records “”[Title/Abstract]) 
OR “”Personal Medical Records””) 
OR “”Personal Electronic Health 
Records “”) OR “”Personal Electronic 
Health Records “”[Title/Abstract])) 
AND ((((((“”Diabetes Mellitus””[Title/
Abstract]) OR “”Diabetes Mellitus, 
Type 1 “”[Title/Abstract]) OR “”Diabetes 
Mellitus, Type 2 “”[Title/Abstract]) 
OR “”Glucose Intolerance “”[Title/
Abstract]) OR “”Diabetic Ketoacidosis 
“”[Title/Abstract]) OR “”Diabetes 
Insipidus””[Title/Abstract])”,
3#
2 ((((((“”Personal Health Record 
“”[Title/Abstract]) OR “”Personal 
Health Records “”[Title/Abstract]) 
OR “”Personal Medical Records””) 
OR “”Personal Electronic Health 
Records “”) OR “”Personal Electronic 
Health Records “”[Title/Abstract])) 
AND ((((((“”Diabetes Mellitus””[Title/
Abstract]) OR “”Diabetes Mellitus, 
Type 1 “”[Title/Abstract]) OR “”Diabetes 
Mellitus, Type 2 “”[Title/Abstract]) 
OR “”Glucose Intolerance “”[Title/
Abstract]) OR “”Diabetic Ketoacidosis 
“”[Title/Abstract]) OR “”Diabetes 
Insipidus””[Title/Abstract]) Filters: 
Randomized Controlled Trial”
4#
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 The studies that have survey the other diseases more 
than diabetes will be excluted.
• Intervention:
 The studies which have examined PHR will be excluded 
from.
• Comparison:
 The studies which have not studied target comparison 
group will be excluded.
• Outcome:
 The studies which have considered unrelated impact 
will be excluded from the study.
• Design:
 Other types of studies other than related studies will be 
excluded.
Data Extraction
The data extraction checklist will be designed based on ar-
ticles data. To ensure all authors who participate in study 
will obtain comparable data, the data of some articles will 
be entered in the pilot checklist. After modifying it, the final 
checklist will be designed and articles data will be extracted 
according to designed checklist.The checklist includes sev-
eral parts as follow: the first part consist of main data of ar-
ticle such as title, corresponding author name, year of study, 
year of publication, place where the study was conducted, 
date on which the study began and ended, age of patients, 
and conflict of interests; the next parts includes items that 
are related to population and outcome of study. The selected 
studies will be divided into two groups, and each of them 
will be assigned to two colleagues for data extraction; each 
of them will independently extract the data from articles. Af-
ter completing data extraction checklist, each of colleagues 
examine other colleague’s data extraction checklist.
Evaluation of Bias Risk in Articles which are Entered 
into Meta-Analysis
If all studies will be RCT, the Cochrane Collaboration’s Risk 
Bias (RoB) tool will be used. The bias risk in studies may 
be assessed using Cochrane Collaboration tool. We will use 
GRADE template making software to facilitate the presenta-
tion of findings of this evaluation. This assessment includes se-
lection bias, relationship bias, performance bias, and biases in 
the identification, the report, and other bias sources including 
intervention compatibility, validity, and reliability of studies.
Analysis and Aggregation of Data
After a systematic search, if meta-analysis is possible, the 
selected studies will be entered into Rev Man and Stata soft-
ware and based on a fixed or randomized model (the fixation 
model will be used in this study), the mean difference and 
confidence interval will be calculated.
Heterogeneity Assessment
The I2 and Chi-squared tests will be used to examine the 
heterogeneity of studies. In this method, according to val-
ues of I2 index, the heterogeneity level is presented as 
follows: low heterogeneity (25%- 50%), medium hetero-
geneity (50%-75%), and high heterogeneity (more than 
75%). If the numerical value of this index will be zero, 
it indicate that the results are homogeneous and if the 
score will be higher, it suggest that the results are hetero-
geneous. If the heterogeneity in results of various studies 
will be confirmed, the analysis will be conducted in sub-
group analysis. Indded, the studies will be grouped based 
on probabilistic factors causing heterogeneity, and sepa-
rate statistical analysis will be performed in each group. In 
the case of meta-analysis, the Forest Plot and Funnel Plot 
will be drawn.
Missing Items
Some articles will be excluded due to various reasons such 
as inaccessibility of full text. The data of missing items will 
not be considered (for primary or secondary outcomes) and 
will not affect results of this study.
Sensitivity Analysis
If necessary, the sensitivity analysis will be performed by 
re-running analyses without using studies that have high bias 
risk.
Evaluation of Quality of Studies
The JADAD criterion will be used to evaluate the quality 
of clinical trials studies. This checklist includes three main 
items including randomization, blindness, and description of 
results; the standard score for first and second items is 2 and 
for the third item is 1. Also, the expert views will be used to 
check the quality of articles. Among the factors which are 
considered for the evaluation of the quality of articles are 
validity of results, method of assigning participants to in-
tervention and control groups, checking that the results are 
achievable, the external validity of results, etc.
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